Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-014107
Filing Date
2025-02-04
Accepted
2025-02-04 21:59:03
Documents
2
Period of Report
2025-01-24

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1564
2 EX-24 omga-ex24.htm EX-24 19174
  Complete submission text file 0000950170-25-014107.txt   22204
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Issuer) CIK: 0001850838 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O OMEGA THERAPEUTICS, INC. 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address
Varsalone Jeffrey T (Reporting) CIK: 0002054819 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-40657 | Film No.: 25590609